Monroe1
1 month ago
Not many posts since then. "As for the industry’s initial reactions on the innovation front, the Pharmaceutical Research and Manufacturers of America (PhRMA) wants to “work with his administration to further strengthen our innovation ecosystem that enables the United States to lead the world in medicine development,” CEO Stephen Ubl said in a statement. “New medicines are transforming our ability to prevent, treat, and cure deadly disease, improving patient lives and helping to avoid the most expensive parts of our health care system.”
"“We are committed to working with the Trump administration and the new Congress to make our health care system work better for patients while preserving our unique ecosystem that enables greater innovation and lower costs for patients,” Ubl said.
Of course, a recent twist in Trump’s later campaign days was the introduction of Robert F. Kennedy Jr. as a prospect to head up healthcare. Kennedy, who scrapped his own campaign for the presidency in August, is widely known for his anti-vaccine rhetoric and conspiracies and was even temporarily banned from Instagram in 2021 for spreading misinformation about COVID-19 vaccines. At a rally in New York, Trump pledged to, if elected, allow Kennedy to “go wild on health” as well as “the medicines.”
Kennedy later delivered a grim message to the FDA on X, formerly Twitter, warning those who “work for the FDA and are part of this corrupt system” to “1. Preserve your records, and 2. Pack your bags.” Today, Fierce Biopharma
Awl416
5 months ago
On July 9, 2024, Soligenix, Inc. (the “Company”) entered into a warrant inducement agreement (the “Inducement Agreement”) with certain holders (the “Holders”) of the Company’s existing Warrant to Purchase Shares of Common Stock (“Existing Warrants”) to purchase shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company. Pursuant to the Inducement Agreement, the Holders agreed to exercise for cash their Existing Warrants to purchase up to 703,125 shares of Common Stock at an exercise price of $6.00 per share during the period from the date of the Inducement Agreement until 1:30 p.m., Eastern Time, on July 9, 2024. The aggregate gross proceeds to be received by the Company will depend on the number of Existing Warrants actually exercised by the Holders. If all of the Existing Warrants are exercised in connection with the Inducement Agreement, the Company would anticipate receiving aggregate gross proceeds of up to approximately $4,218,750 from the exercise of the Existing Warrants before deducting financial advisory fees and other expenses payable by us. There is, however, no guarantee that all of the Existing Warrants will be exercised by the Holder in accordance with the Inducement Agreement.